{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:31:40Z","timestamp":1790076700937,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.antiviral.2018.12.004","type":"journal-article","created":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T02:27:53Z","timestamp":1544408873000},"page":"30-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection"],"prefix":"10.1016","volume":"162","author":[{"given":"Long","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-783X","authenticated-orcid":false,"given":"Kimiyasu","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.12.004_bib1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1089\/vim.2016.0151","article-title":"Interaction of immunoglobulin with cytomegalovirus-infected Cells","volume":"30","author":"Aiba","year":"2017","journal-title":"Viral Immunol."},{"key":"10.1016\/j.antiviral.2018.12.004_bib2","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/ajt.12809","article-title":"Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial","volume":"14","author":"Andreassen","year":"2014","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.12.004_bib3","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2011.03674.x","article-title":"Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials","volume":"11","author":"Brennan","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.12.004_bib4","doi-asserted-by":"crossref","first-page":"E401","DOI":"10.1111\/j.1399-0012.2011.01446.x","article-title":"Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen","volume":"25","author":"Carvalho","year":"2011","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.antiviral.2018.12.004_bib5","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1101\/gad.196147.112","article-title":"Dynein mediates the localization and activation of mTOR in normal and human cytomegalovirus-infected cells","volume":"26","author":"Clippinger","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.antiviral.2018.12.004_bib6","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.01913-10","article-title":"The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection","volume":"85","author":"Clippinger","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.12.004_bib7","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1128\/JVI.05102-11","article-title":"Human cytomegalovirus infection maintains mTOR activity and its perinuclear localization during amino acid deprivation","volume":"85","author":"Clippinger","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.12.004_bib8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/1348-0421.12043","article-title":"Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens","volume":"57","author":"Daikoku","year":"2013","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.antiviral.2018.12.004_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17050735","article-title":"Sirolimus and everolimus pathway: reviewing candidate genes influencing their intracellular effects","volume":"17","author":"Granata","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.antiviral.2018.12.004_bib10","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.12.004_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/TP.0b013e318276a1ef","article-title":"Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients","volume":"95","author":"Havenith","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.12.004_bib12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/ajt.13649","article-title":"Impact of everolimus and low-dose cyclosporin on cytomegalovirus replication and disease in pediatric renal transplantation","volume":"16","author":"Hocker","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.12.004_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00007691-200410000-00007","article-title":"Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation","volume":"26","author":"Kovarik","year":"2004","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.antiviral.2018.12.004_bib14","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1128\/JVI.02079-06","article-title":"AMPK-mediated inhibition of mTOR kinase is circumvented during immediate-early times of human cytomegalovirus infection","volume":"81","author":"Kudchodkar","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.12.004_bib15","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1128\/JVI.78.20.11030-11039.2004","article-title":"Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase","volume":"78","author":"Kudchodkar","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.12.004_bib16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1124\/jpet.109.160630","article-title":"Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir","volume":"333","author":"Kuramoto","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.antiviral.2018.12.004_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/TP.0b013e3181aacd22","article-title":"Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients","volume":"88","author":"Lehmkuhl","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.12.004_bib18","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1128\/JVI.02733-09","article-title":"Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication","volume":"84","author":"Moorman","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.12.004_bib19","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/TP.0b013e31824810e6","article-title":"Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients","volume":"93","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.12.004_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/tid.12494","article-title":"Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid","volume":"18","author":"Radtke","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.12.004_bib21","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/ajt.12725","article-title":"New cell-signaling pathways for controlling cytomegalovirus replication","volume":"14","author":"Roy","year":"2014","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.12.004_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.transproceed.2016.10.018","article-title":"Comparison of mizoribine and mycophenolate mofetil with a tacrolimus-based immunosuppressive regimen in living-donor kidney transplantation recipients: a retrospective study in China","volume":"49","author":"Shi","year":"2017","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.12.004_bib23","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1128\/JVI.00435-11","article-title":"Neutralizing anti-gH antibody of Varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency","volume":"85","author":"Shiraki","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.12.004_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0042-6822(87)90423-5","article-title":"The immediate early proteins of varicella-zoster virus","volume":"156","author":"Shiraki","year":"1987","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.12.004_bib25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.7164\/antibiotics.44.550","article-title":"Effect of FK-506 on replication of human cytomegalovirus in vitro","volume":"44","author":"Shiraki","year":"1991","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.antiviral.2018.12.004_bib26","first-page":"1682","article-title":"Effects of cyclosporine, azathioprine, mizoribine, and prednisolone on replication of human cytomegalovirus","volume":"22","author":"Shiraki","year":"1990","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.12.004_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01310762","article-title":"Immunosuppressive dose of azathioprine inhibits replication of human cytomegalovirus in vitro","volume":"117","author":"Shiraki","year":"1991","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2018.12.004_bib28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jmv.1890340413","article-title":"Antibody response to the immediate early protein of cytomegalovirus in renal transplant recipients","volume":"34","author":"Shiraki","year":"1991","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.12.004_bib29","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1111\/ajt.13835","article-title":"Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial","volume":"16","author":"Strueber","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.12.004_bib30","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.12.004_bib31","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.transproceed.2015.12.117","article-title":"Efficacy and safety of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids in renal transplantation: a Japanese multicenter study","volume":"48","author":"Ushigome","year":"2016","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.antiviral.2018.12.004_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1517\/14740338.2016.1132698","article-title":"Safety of mTOR inhibitors in adult solid organ transplantation","volume":"15","author":"Ventura-Aguiar","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.antiviral.2018.12.004_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1399-3062.2009.00448.x","article-title":"Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study","volume":"12","author":"Vigano","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.12.004_bib34","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients","volume":"5","author":"Vitko","year":"2005","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2018.12.004_bib35","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/01.tp.0000219703.39149.85","article-title":"Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials","volume":"81","author":"Webster","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2018.12.004_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jiac.2015.01.012","article-title":"Functional differences between antiviral activities of sulfonated and intact intravenous immunoglobulin preparations toward varicella-zoster virus and cytomegalovirus","volume":"21","author":"Yajima","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.antiviral.2018.12.004_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10157-012-0669-4","article-title":"The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients","volume":"17","author":"Yoshimura","year":"2013","journal-title":"Clin. Exp. Nephrol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T02:28:13Z","timestamp":1548383293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218305722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":37,"alternative-id":["S0166354218305722"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.12.004","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}